GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexin Pharmaceuticals AB (OSTO:ANNX) » Definitions » Stock Based Compensation

Annexin Pharmaceuticals AB (OSTO:ANNX) Stock Based Compensation : kr0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Annexin Pharmaceuticals AB Stock Based Compensation?

Annexin Pharmaceuticals AB's Stock Based Compensation for the three months ended in Mar. 2024 was kr0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.00 Mil.


Annexin Pharmaceuticals AB Stock Based Compensation Historical Data

The historical data trend for Annexin Pharmaceuticals AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annexin Pharmaceuticals AB Stock Based Compensation Chart

Annexin Pharmaceuticals AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only - - - - -

Annexin Pharmaceuticals AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Annexin Pharmaceuticals AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.


Annexin Pharmaceuticals AB Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Annexin Pharmaceuticals AB's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Annexin Pharmaceuticals AB (OSTO:ANNX) Business Description

Traded in Other Exchanges
N/A
Address
Norrtullsgatan 6, Stockholm, SWE, SE-113 29
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.

Annexin Pharmaceuticals AB (OSTO:ANNX) Headlines

From GuruFocus

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

By Stock market mentor Stock market mentor 01-17-2023